GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » Cyclically Adjusted PB Ratio

Pfizer (Pfizer) Cyclically Adjusted PB Ratio : 1.75 (As of Apr. 27, 2024)


View and export this data going back to 1951. Start your Free Trial

What is Pfizer Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Pfizer's current share price is $25.40. Pfizer's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $14.53. Pfizer's Cyclically Adjusted PB Ratio for today is 1.75.

The historical rank and industry rank for Pfizer's Cyclically Adjusted PB Ratio or its related term are showing as below:

PFE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.74   Med: 2.87   Max: 4.7
Current: 1.74

During the past years, Pfizer's highest Cyclically Adjusted PB Ratio was 4.70. The lowest was 1.74. And the median was 2.87.

PFE's Cyclically Adjusted PB Ratio is ranked worse than
51.62% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs PFE: 1.74

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Pfizer's adjusted book value per share data for the three months ended in Dec. 2023 was $15.766. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $14.53 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pfizer Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Pfizer's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Cyclically Adjusted PB Ratio Chart

Pfizer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.08 3.04 4.59 3.69 1.98

Pfizer Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.69 2.87 2.54 2.28 1.98

Competitive Comparison of Pfizer's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted PB Ratio falls into.



Pfizer Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Pfizer's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=25.40/14.53
=1.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Pfizer's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=15.766/129.4194*129.4194
=15.766

Current CPI (Dec. 2023) = 129.4194.

Pfizer Quarterly Data

Book Value per Share CPI Adj_Book
201403 12.159 99.695 15.784
201406 12.081 100.560 15.548
201409 12.373 100.428 15.945
201412 11.329 99.070 14.800
201503 10.926 99.621 14.194
201506 10.842 100.684 13.936
201509 10.823 100.392 13.952
201512 10.477 99.792 13.587
201603 10.181 100.470 13.114
201606 10.344 101.688 13.165
201609 10.428 101.861 13.249
201612 9.806 101.863 12.459
201703 9.809 102.862 12.342
201706 9.810 103.349 12.285
201709 10.191 104.136 12.665
201712 11.923 104.011 14.836
201803 11.795 105.290 14.498
201806 11.900 106.317 14.486
201809 12.334 106.507 14.987
201812 11.088 105.998 13.538
201903 10.579 107.251 12.766
201906 10.707 108.070 12.822
201909 11.767 108.329 14.058
201912 11.407 108.420 13.616
202003 11.709 108.902 13.915
202006 11.584 108.767 13.784
202009 11.744 109.815 13.841
202012 11.359 109.897 13.377
202103 12.267 111.754 14.206
202106 12.510 114.631 14.124
202109 13.490 115.734 15.085
202112 13.737 117.630 15.114
202203 14.742 121.301 15.729
202206 15.592 125.017 16.141
202209 16.506 125.227 17.059
202212 17.034 125.222 17.605
202303 17.887 127.348 18.178
202306 17.541 128.729 17.635
202309 17.169 129.860 17.111
202312 15.766 129.419 15.766

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pfizer  (NYSE:PFE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Pfizer Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Pfizer's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer (Pfizer) Business Description

Industry
Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Executives
Scott Gottlieb director MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Christoffel Boshoff officer: Executive Vice President 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Jennifer B. Damico officer: SVP & Controller C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Payal Sahni officer: Executive Vice President ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Carapezzi William R Jr officer: Executive Vice President 600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921
Douglas M Lankler officer: Senior Vice President PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Mikael Dolsten officer: Senior Vice President 5 GIRALDA FARMS, MADISON NJ 07940
David M Denton officer: Chief Financial Officer & EVP 1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
William Pao officer: Executive Vice President C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Michael Mcdermott officer: Executive Vice President C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017
Rady A Johnson officer: Executive Vice President PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Alexander R Mackenzie officer: Executive Vice President C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Sally Susman officer: Senior Vice President 767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153
Angela Hwang officer: Group President 235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017
John D Young officer: Business Unit President C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017

Pfizer (Pfizer) Headlines

From GuruFocus

Pfizer Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Pfizer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc at Truist BioPharma Symposium Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc's Dividend Analysis

By GuruFocus Research 01-24-2024

Q2 2023 Pfizer Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc to Review Oral GLP-1 Data Call Transcript

By GuruFocus Research 01-23-2024

Pfizer Inc at Wells Fargo Healthcare Conference Transcript

By GuruFocus Research 01-23-2024